A prospective study of pulmonary function in patients receiving mitomycin

Chest

Volumn 109, Issue 4, 1996, Pages 939-944

  Castro, Mario ^a,b,f   Veeder, Michael H ^a,c   Mailliard, James A ^a,d   Tazelaar, Henry D ^a   Jett, James R ^a,e  

^a MAYO CLINIC CANCER CENTER   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Illinois Oncology Research Association CCOP   (United States)

^d CREIGHTON UNIVERSITY   (United States)

^e UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^f WASHINGTON UNIVERSITY   (United States)

Author keywords

diffusing capacity; lung cancer; mitomycin; pulmonary toxicity

Indexed keywords

CISPLATIN; CORTICOSTEROID; MITOMYCIN; VINBLASTINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXPIRATORY FLOW; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG CARCINOMA; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY; SQUAMOUS CELL CARCINOMA;

EID: 0029989177     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.109.4.939     Document Type: Article

References (35)

1. Spain RC. The case for mitomycin in non-small cell lung cancer. Oncology 1993; 50:35-52
2. Samson MK, Comis RL, Baker LH, et al. Mitomycin-C in advanced adenocarcinoma and large cell carcinoma of the lung. Cancer Treat Rep 1978; 62:163-65
3. Sheldon R, Slaughter D. A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy-treated patients with adenocarcinoma. Cancer 1986; 58:1428-36
4. Lesesne JB, Rothschild N, Erickson B, et al. Cancer associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol 1989; 7:781-89
5. Buzdar AU, Legha SS, Tashima CK, et al. Adriamycin and mitomycin-C: possible synergistic cardiotoxicity. Cancer Treat Rep 1970; 62:1005-08
6. Simasoto Y, Baba K, Watanabe S. Pulmonary lesions produced by antitumor drugs: studies on autopsy cases. Jpn J Cancer Clin 1971; 17:21-34
7. Ginsberg SJ, Comis RL. The pulmonary toxicity of antineoplastic agents. Semin Oncol 1982; 9:34-51
8. Cooper JAD Jr, White DA, Matthay RA. Drug-induced pulmonary disease: I. Cytotoxic drugs. Am Rev Respir Dis 1986; 133:321-40
9. Verweij J, van der Burg MEL, Pinedo HM. Mitomycin-C induced hemolytic uremic syndrome: six case reports and review of the literature on renal, pulmonary and cardiac side effects of the drug. Radiother Oncol 1987; 8:33-41
10. Orwoll ES, Kiessling PJ, Patterson JR. Interstitial pneumonia from mitomycin. Ann Intern Med 1978; 89:352-55
11. Buzdar AU, Legha SS, Luna MA, et al. Pulmonary toxicity of mitomycin. Cancer 1980; 45:236-44
12. Twohig KJ, Matthay RA. Pulmonary effects of cytotoxic agents other than bleomycin: drug-induced pulmonary disease. Clin Chest Med 1990; 11:31-54
13. Verweij J, van Zanten T, Souren T, et al. Prospective study on the dose relationship of mitomycin C-induced interstitial pneumonitis. Cancer 1987; 60:756-61
14. Gunstream SR, Seidenfeld JJ, Sobonya RE, et al. Mitomycin-associated lung disease. Cancer Treat Rep 1983; 67:301-04
15. Kuebler JP, Chang AYC, Pandya KJ, et al. Pulmonary toxicity associated with a mitomycin-C containing regimen. Clin Res 1982; 30:859A
16. Chang AY, Kuebler JP, Pandya KJ, et al. Pulmonary toxicity induced by mitomycin C is highly responsive to glucocorticoids. Cancer 1986; 57:2285-90
17. Veeder MH, Jett JR, Su JQ, et al. A phase III trial of mitomycin C alone versus mitomycin C, vinblastine, and cisplatin for metastatic squamous cell lung carcinoma. Cancer 1992; 70:2281-87
18. Miller AB, Hoogstraten B, Statquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47:207-14.
19. American Thoracic Society. Standardization of spirometry - 1987 update. Am Rev Respir Dis 1987; 136:1285-98
20. Miller A. Pulmonary function tests in clinical and occupational lung disease. Orlando, Fla: Grune & Stratton, 1986; 146-48
21. Knudson RJ, Lebowitz MD, Holberg CJ, et al. Changes in normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983; 127:725-34
22. Miller A, Thornton JC, Warshaw R, et al. Single breath diffusing capacity in a representative sample of the population of Michigan, a large industrial state. Am Rev Respir Dis 1983; 127:270-77
23. Beck KC, Hyatt RE, Staats BA, et al. Carbon monoxide diffusing capacity of the lungs determined by single-breath and steady-state exercise methods. Mayo Clin Proc 1989; 64:51-9
24. American Thoracic Society. Single breath carbon monoxide diffusing capacity (transfer factor): recommendations for a standard technique. Am Rev Respir Dis 1987; 136:1299-1307
25. Cotes JE. Lung function assessment and application in medicine. 4th ed. Oxford: Blackwell Scientific Publications, 1979; 225-50
26. Snedecor GW, Cochran WG. Statistical methods, 7th ed. Ames: Iowa State University Press, 1980; 138-40
27. Fisher DL, van Belle C. Biostatistics: a methodology for the health sciences. New York: Wiley 1993, 185-6
28. Peto R. Rank tests of maximal power against Lehmann-type alternatives. Biometrika 1972; 59:472-75
29. Kaplan E, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958; 53:457-81
30. Luedke D, Mclaughlin TT, Daughadav C, et al. Mitomycin C and vindesine associated pulmonary toxicity with variable clinical expression. Cancer 1985; 55:542-45
31. Kris MG, Pablo D, Gralla RJ, et al. Dyspnea following vinblastine or vindesine administration in patients receiving mitomycin plus vinca alkaloid combination therapy. Cancer Treat Rep 1984; 68:1029-31
32. Rao SX, Ramaswamy G, Levin M, et al. Fatal acute respiratory failure after vinblastine-mitomycin therapy in lung carcinoma. Arch Intern Med 1985; 145:1905-07
33. Pritsos CA, Sartorelli AC. Generation of reactive oxygen radicals through bioactivation of mitomycin antibiotics. Cancer Res 1986; 436:3528-32
34. Murgo AJ. Thrombotic microangiopathy in the cancer patient including those induced by chemotherapeutic agents. Semin Hematol 1987; 24:161-77
35. Gralla RJ, Bolton JS, Clark RA, et al. Mitomycin in non-small cell lung cancer (NSCLC): does pulmonary toxicity limit its use? Proc Am Soc Clin Oncol 1992; 11:292A